Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. (Q43855068)
Jump to navigation
Jump to search
scientific article published in December 2001
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. |
scientific article published in December 2001 |
Statements
Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi (English)
R Dietze
S F Carvalho
L C Valli
J Berman
T Brewer
W Milhous
J Sanchez
B Schuster
1 December 2001